<DOC>
	<DOCNO>NCT02458339</DOCNO>
	<brief_summary>The goal clinical research study establish maximum tolerate dose ( MTD ) direct administration methotrexate fourth ventricle brain patient recurrent malignant brain tumor include medulloblastoma , primitive neuroectodermal tumor ( PNET ) , atypical teratoid/rhabdoid tumor ( AT/RT ) , ependymoma . Methotrexate design block cancer cell divide , may slow stop growth spread throughout body . This may cause cancer cell die .</brief_summary>
	<brief_title>Methotrexate Infusion Into Fourth Ventricle Children With Recurrent Malignant Fourth Ventricular Brain Tumors</brief_title>
	<detailed_description>If participant eligible take part study , participant surgery place catheter ommaya reservoir . The ommaya reservoir catheter system allow drug administer directly part brain . This catheter use infusion methotrexate directly 4th ventricle brain , 1 4 connect fluid-filled cavity brain . If study doctor think necessary , base location tumor , tumor may also remove participant already anesthesia catheter place . Study Drug Administration : The participant receive 3 cycle intraventricular methotrexate fourth ventricle . Each cycle 4 week duration . During first 3 week ( Day 1-7 weekly ) methotrexate infuse twice weekly day 1 4 ( +/-2 day ) . The 4th week rest week . Methotrexate infuse ommaya reservoir catheter directly 4th ventricle brain start minimum 7 day catheter placement surgery . A MRI do confirm adequate cerebrospinal fluid flow . The infusion last 3 minute time . If participant already ommaya catheter , methotrexate begin MRI confirm adequate cerebrospinal fluid flow . Study Visits : Prior Cycle 1 : - Medical history review update health record - A physical vital sign neurological exam do . - Blood ( 1 teaspoon ) drawn routine test - A MRI scan brain spine do check status disease . On day Methotrexate Infusion : - A physical vital sign neurological exam do - A Ommaya reservoir tap ( catheter place Ommaya reservoir give methotrexate infusion ) . - Cerebrospinal fluid ( 1 teaspoon ) collect routine test . Within 7 day complete Cycle 3 : - A physical vital sign neurological exam do . - A lumbar puncture do . - A MRI scan brain spine do check status disease . Length Study : The participant receive 3 cycle methotrexate , long doctor think best interest . The participant longer able receive study drug disease get bad , intolerable side effect occur , unable follow study direction . This investigational study . Methotrexate FDA approve commercially available infusion directly brain tumor . The infusion methotrexate 4th ventricle brain investigational , Up 18 patient enrol study . All enrol Children 's Memorial Hermann Hospital .</detailed_description>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>1 . Diagnosis : Patients histologically verified medulloblastoma , primitive neuroectodermal tumor ( PNET ) , atypical teratoid/rhabdoid tumor ( AT/RT ) , ependymoma , choroid plexus carcinoma recurrence progression involve brain /or spine . Patients tumor present diagnosis posterior fossa relapse posterior fossa eligible . Patients initially present disease posterior fossa relapse outside posterior fossa also eligible . 2 . Patient must either measurable evaluable tumor assess MRI brain total spine . 3 . An implanted catheter fourth ventricle attach Ommaya reservoir agreement one place . 4 . A minimum 7 day last dose systemic chemotherapy and/or radiation therapy first infusion methotrexate fourth ventricle . 5 . Life expectancy least 12 week opinion PI . 6 . Lansky score 50 great ≤16 year age Karnofsky score 50 great &gt; 16 year age . 7 . Existing neurological deficit weakness , gait instability , cranial nerve deficit , problem cause patient 's disease previous treatment must stable minimum 1 week prior study enrollment . 8 . Patients must recover acute toxic effect prior anticancer chemotherapy . 9 . Adequate bone marrow function define peripheral absolute neutrophil count ( ANC ) ≥ 500/ µL , platelet count ≥ 50,000/ µL ( transfusion independent ) , hemoglobin ≥ 9.0 gm/dL ( may receive RBC transfusion ) 10 . Patient patient 's legal representative , parent ( ) , guardian able provide write informed consent . 1 . Enrolled another treatment protocol 2 . Has receive another investigational chemotherapy agent radiation therapy 7 day prior methotrexate infusion fourth ventricle 3 . Evidence untreated infection 4 . Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Brain tumor</keyword>
	<keyword>Malignant Fourth Ventricular Brain Tumors</keyword>
</DOC>